Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Priority Review Designations In US: Third Quarter Spike Continues In 2017

Executive Summary

Third quarter saw record total of 26 announcements for priority review designations; drop-off now likely.

You may also be interested in...



Breakthrough, Priority Review Designations Could Set High-Water Marks In 2018

Announcements of designations for both US FDA's expedited pathway are on torrid paces through first half of 2018. 

Breakthrough Therapy Designations Set Quarterly Record

US FDA granted designations for several products based on late-stage data; with at least 19 breakthrough therapy designations, five-year-old program sets another record in first quarter of 2018.

US FDA Sets Records With Breakthrough Therapy, Priority Review Designations In 2017

Cancer therapies captured a majority of both the breakthrough therapy and priority review designations awarded by the agency.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS121874

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel